(Q33960082)

30 July 2017

1 reference

title

Plasminogen activator inhibitor-1 and the kidney (English)

1 reference

30 July 2017

1 reference

Allison A Eddy

1

1 reference

PubMed ID

12110504

30 July 2017

language of work or name

1 reference

1 August 2002

1 reference

American Journal of Physiology - Renal Physiology

30 July 2017

1 reference

30 July 2017

283

1 reference

30 July 2017

2

1 reference

30 July 2017

F209-20

1 reference

Insulin and angiotensin II are additive in stimulating TGF-beta 1 and matrix mRNAs in mesangial cells

30 July 2017

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

The urokinase-type plasminogen activator system in cancer metastasis: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Complex carbohydrates of the extracellular matrix structures, interactions and biological roles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Transcriptional regulation of plasminogen activator inhibitor type 1 gene by insulin: insights into the signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Expression of plasminogen activator-inhibitor-1 (PAI-1) during cellular remodeling in proliferative glomerulonephritis in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Transforming growth factor beta in tissue fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen system

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Cyclic strain-induced plasminogen activator inhibitor-1 (PAI-1) release from endothelial cells involves reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Reversal of lesions of diabetic nephropathy after pancreas transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Human plasma fibronectin as a substrate for human urokinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Antigen-driven lymphocyte recruitment to the lung is diminished in the absence of urokinase-type plasminogen activator (uPA) receptor, but is independent of uPA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Therapy with antisense TGF-beta1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

LRP: a multifunctional scavenger and signaling receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Angiotensin converting enzyme inhibitor suppresses glomerular transforming growth factor beta receptor expression in experimental diabetes in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Transcriptional regulation of plasminogen activator inhibitor type-1 mRNA in Hep G2 cells by epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Regulation of plasminogen activator inhibitor-1 and urokinase by hyaluronan fragments in mouse macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

The plasminogen activator system: biology and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Effect of anti-transforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Plasminogen-activator inhibitor type 1 and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

E2F1-mediated transcriptional inhibition of the plasminogen activator inhibitor type 1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Thrombolytic therapy: current status (1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Plasminogen activator inhibitor type-1 and interleukin-6 in haemolytic uraemic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Glucocorticoid-modulated gene expression of tissue- and urinary-type plasminogen activator and plasminogen activator inhibitor 1 and 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

The kidney is a major site of alpha(2)-antiplasmin production

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Motifs resembling hepatocyte nuclear factor 1 and activator protein 3 mediate the tissue specificity of the human plasminogen gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Biology and biochemistry of proteinases in tumor invasion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Biological Activation of pro-HGF (Hepatocyte Growth Factor) by Urokinase Is Controlled by a Stoichiometric Reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Protease resistance and conformation of laminin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Angiotensin II blockade and low-protein diet produce additive therapeutic effects in experimental glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

A total fibrinogen deficiency is compatible with the development of pulmonary fibrosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Protein C inhibitor is expressed in tubular cells of human kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Tissue plasminogen activator-induced secretion of type-1 plasminogen activator inhibitor in cultured human fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Urokinase synthesis and binding by glomerular epithelial cells in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Mechanism of fibrosis in experimental tacrolimus nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Cutting edge: evidence for a signaling partnership between urokinase receptors (CD87) and L-selectin (CD62L) in human polymorphonuclear neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Platelet‐derived Growth Factor Increases Plasminogen Activator Inhibitor‐1 Activity and mRNA in Rat Cultured Vascular Smooth Muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Thrombogenic alleles, Escherichia coli O157:H7 infections, and hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Activation of the serine proteinase system in chronic kidney rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Extracellular matrix accumulation in immune-mediated tubulointerstitial injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

A laboratory model of toxin-induced hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Plasminogen activator inhibitor-1 gene polymorphism 4G/4G genotype and lupus nephritis in Chinese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Different expression of the plasminogen activation system in renal thrombotic microangiopathy and the normal human kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Endothelin-1 enhances plasminogen activator inhibitor-1 production by human brain endothelial cells via protein kinase C-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Interstitial inflammation and fibrosis in rats with diet-induced hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

Interstitial fibrosis in mice with overload proteinuria: Deficiency of TIMP-1 is not protective

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00032.2002

10.1152/AJPRENAL.00032.2002

21 January 2018

Identifiers

DOI

0 references

PubMed ID

12110504

1 reference

PubMed ID

12110504